Appili Therapeutics, Inc. (APLIF)
0.0055
0.00 (0.00%)
USD |
OTCM |
Oct 16, 16:00
Appili Therapeutics Total Liabilities (Quarterly) : 14.32M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.32M |
| March 31, 2026 | 13.83M |
| December 31, 2025 | 12.35M |
| September 30, 2025 | 11.76M |
| June 30, 2025 | 12.11M |
| March 31, 2025 | 11.42M |
| December 31, 2024 | 10.93M |
| September 30, 2024 | 10.86M |
| June 30, 2024 | 10.68M |
| March 31, 2024 | 9.174M |
| December 31, 2023 | 8.949M |
| September 30, 2023 | 8.620M |
| June 30, 2023 | 8.266M |
| March 31, 2023 | 7.780M |
| December 31, 2022 | 5.863M |
| September 30, 2022 | 5.065M |
| June 30, 2022 | 6.761M |
| Date | Value |
|---|---|
| March 31, 2022 | 9.249M |
| December 31, 2021 | 9.339M |
| September 30, 2021 | 12.68M |
| June 30, 2021 | 4.880M |
| March 31, 2021 | 4.427M |
| December 31, 2020 | 3.270M |
| September 30, 2020 | 2.008M |
| June 30, 2020 | 2.409M |
| March 31, 2020 | 1.636M |
| December 31, 2019 | 1.796M |
| September 30, 2019 | 1.466M |
| June 30, 2019 | 1.745M |
| March 31, 2019 | 1.808M |
| December 31, 2018 | 2.562M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | 1.802M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| InMed Pharmaceuticals, Inc. | 1.955M |
| NervGen Pharma Corp. | 51.39M |
| Milestone Pharmaceuticals, Inc. | 163.41M |
| Clearmind Medicine, Inc. | 3.961M |
| Lexaria Bioscience Corp. | 0.4371M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 0.9129M |
| Shareholders Equity (Quarterly) | -13.41M |
| Debt to Equity Ratio | -0.7005 |
| Current Ratio | 0.0653 |
| Net Debt Paydown Yield | -11.67% |